1. Home
  2. CRNX

CRNX

Crinetics Pharmaceuticals Inc.

Logo Crinetics Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 3.3B IPO Year: 2018
Target Price: $56.25 AVG Volume (30 days): 807.1K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.69 EPS Growth: N/A
52 Week Low/High: $15.71 - $49.58 Next Earning Date: 05-02-2024
Revenue: $4,013,000 Revenue Growth: -15.28%
Revenue Growth (this year): -45.75% Revenue Growth (next year): 1115.76%

Share on Social Networks:

Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Struthers Richard Scott CRNX President & CEO Apr 4 '24 Sell $49.17 40,951 $2,013,560.67 237,835 SEC Form 4
Pizzuti Dana CRNX Chief Med and Dev Officer Mar 20 '24 Sell $45.89 4,375 $200,768.75 28,500 SEC Form 4
Pizzuti Dana CRNX Chief Med and Dev Officer Mar 20 '24 Sell $43.28 10,000 $432,800.00 28,500 SEC Form 4
Pizzuti Dana CRNX Chief Med and Dev Officer Mar 20 '24 Sell $43.69 714 $31,194.66 27,786 SEC Form 4
Betz Stephen F. CRNX Chief Scientific Officer Jan 25 '24 Sell $37.26 3,000 $111,780.00 73,298 SEC Form 4
Betz Stephen F. CRNX Chief Scientific Officer Dec 26 '23 Sell $35.89 3,000 $107,670.00 79,298 SEC Form 4
Wilson Marc CRNX CFO Nov 1 '23 Sell $28.75 10,000 $287,500.00 95,601 SEC Form 4